Drugs that contain Atogepant
1. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET;ORAL
More Information on Dosage
QULIPTA family patents
